Sarepta Therapeutics (SRPT) Gains from Investment Securities (2010 - 2025)

Sarepta Therapeutics' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $20.0 million for Q4 2025.

• In Q4 2025, Gains from Investment Securities fell 15.75% year-over-year to $20.0 million; the TTM figure through Dec 2025 stood at $44.4 million (down 55.06% YoY), while the FY2025 annual figure was $488192.0, down 94.51% from the prior year.
• Gains from Investment Securities was $20.0 million for Q4 2025 at Sarepta Therapeutics, up from $5.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $80.2 million in Q4 2023 to a low of -$13.1 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged $6.1 million across 5 years, with a median of $925167.0 in 2022.
• The sharpest annual moves came in 2021 and 2022: Gains from Investment Securities slumped 728.17% in 2021, then surged 4774955.56% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$4.5 million in 2021, then plunged by 194.48% to -$13.1 million in 2022, then jumped by 710.65% to $80.2 million in 2023, then slumped by 70.39% to $23.7 million in 2024, then dropped by 15.75% to $20.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $20.0 million (Q4 2025), $5.2 million (Q3 2025), and -$4.6 million (Q2 2025), per Business Quant data.